The Corona Remedies share price debut turned heads on Dalal Street as the stock made a confident entry into the secondary market. Investors tracking Corona Remedies' share price today witnessed a strong opening, with the stock listing at a sharp premium over its IPO price.
The debut reflected the solid demand seen during the public issue and continued momentum in the broader market environment.
Market Performance: Corona Remedies Share Price Today on NSE and BSE
The Corona Remedies share price on the NSE opened firmly, delivering a strong premium right at the bell.
Here’s how the listing unfolded:
- NSE listing price: ₹1,470 per share
- Premium over IPO price: 38.42%
- BSE listing price: ₹1,452 per share
- Premium on BSE: 36.72%
Post listing, the company’s market capitalisation stood at ₹8,880.44 crore, marking a confident start for the pharmaceutical firm in the public markets.
Main News: Corona Remedies IPO Listing Draws Strong Investor Response
The Corona Remedies IPO listing followed an exceptionally strong response in the primary market. The issue was subscribed to 137.04 times during the subscription window from December 8 to December 10, underlining heavy demand across investor categories.
Key IPO details remain central to today’s listing story:
- Issue size: ₹655.37 crore
- Price band: ₹1,008 to ₹1,062 per share
- Anchor investment raised earlier: ₹195 crore
The strength of the subscription translated clearly into the Corona Remedies share price debut, with the stock opening well above its issue price on both major exchanges.
Corona Remedies Share Price BSE Today: Parallel Strength Across Exchanges
While the spotlight remained on the NSE, the Corona Remedies share price on the BSE today also reflected similar enthusiasm.
Listing at ₹1,452 per share, the stock showed consistency across platforms, reinforcing the depth of investor participation seen during the IPO process.
The parallel pricing on NSE and BSE suggested broad-based interest rather than exchange-specific activity.
Company Details: Business Overview and Product Presence
Headquartered in Ahmedabad, Corona Remedies operates in the pharmaceutical formulations space. The company is engaged in the development, manufacturing, and marketing of medicines across a wide range of therapeutic areas.
Its presence spans key areas such as:
- Women’s healthcare
- Cardio-diabeto therapies
- Pain management
- Urology
- Other chronic therapy segments
As of December 2024, the company’s portfolio included 67 brands, giving it a diversified footprint across treatment categories.
Summary: Corona Remedies Share Price Debut Sets Strong Opening Tone
The Corona Remedies share price today marked a confident beginning, with the stock listing at a 38% premium on the NSE and showing similar strength on the BSE. Backed by a 137.04x subscription, the IPO debut reflected sustained investor interest carried over from the primary market.
With a market capitalisation of ₹8,880.44 crore post listing and a broad-based product portfolio, Corona Remedies entered the listed space on a firm footing, making its debut one of the notable market events of the session.
Easy & quick
Leave A Comment?